Ivonescimab: 70.8% ORR in mCRC Phase II; HARMONi-6 OS HR 0.66 vs tislelizumab

Summit Therapeutics Inc.

Phase II AK112-206 in 1L mCRC: ORR 70.8%, DCR 100.0% in evaluable patients (n=48); 9-month PFS rate 76.1% for 20 mg/kg arm.
HARMONi-6 Phase III in squamous NSCLC: OS HR 0.66 (p=0.0017) vs tislelizumab + chemo; 24-month OS rates 64.7% vs 48.6%.
Ivonescimab + chemo reduced risk of death by 34% vs tislelizumab; first Phase III to show significant OS benefit over anti-PD-1 + chemo in 1L NSCLC.
Safety profiles manageable; no new safety signals; TRAEs leading to discontinuation in HARMONi-6: 5.3% vs 4.5%.
Data presented at ASCO 2026; HARMONi-6 results simultaneously published in The Lancet; Summit to host conference call June 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.